Streetwise Expert Interviews

George Zavoico

Opportunities in Cancer Immunotherapy Throttle Up: George Zavoico of JonesTrading

Biotech investors are abuzz over immune checkpoint inhibitors and T-cell therapies, but which ones do you pick? JonesTrading Institutional Services Senior Equity Analyst George Zavoico is moving rapidly to initiate coverage on some key names in this space, and is casting a wide net in hopes of catching winners. In this interview with The Life Sciences Report, Zavoico delineates some movers and shakers in the cancer immunotherapy field, and recommends investors keep their pencils sharp and eyes open as data emerge over the next year or two.

(6/24/15) More >
Read More Streetwise Interviews

Capitalize on Comeback Stories in Micro-Cap Biotech: Joe Pantginis of ROTH Capital Partners

Joseph Pantginis of ROTH Capital Partners recognizes the characteristics that make micro-cap biotech companies move up the ladder in market valuation, and discusses five names with development programs capable of generating dramatic growth. (6/17/15) More >

Newsletter Briefs

"INO has a broad platform that includes an IL-12 DNA vaccine and other DNA vaccines for both cancer and infectious diseases." (6/24/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with George Zavoico Moreá>

"The intriguing component of SNSS' VALOR study is a nice survival benefit seen in patients 60 years and older." (6/17/15) Sunesis Pharmaceuticals Inc. - The Life Sciences Report Interview with Joe Pantginis Moreá>

"RNN is playing in the right space of targeted therapies." (6/17/15) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Joe Pantginis Moreá>

"IMUC is a very intriguing name." (6/17/15) ImmunoCellular Therapeutics Ltd. - The Life Sciences Report Interview with Joe Pantginis Moreá>

"CPXX is improving the current standard of care in acute myeloid leukemia." (6/17/15) Celator Pharmaceuticals Inc. - The Life Sciences Report Interview with Joe Pantginis Moreá>

"Following the 12-week endpoint, CANF's CF101 continued accumulation and the responses have become much better." (6/17/15) Can-Fite BioPharma Ltd. - The Life Sciences Report Interview with Joe Pantginis Moreá>

"INO has had a number of successes clinically and marquee collaborations that have led to its market cap being what it is today." (5/20/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Ross Silver Moreá>

"SNGX is an exciting company; it is rare to find a micro cap with such a diverse and broad clinical pipeline." (5/20/15) Soligenix Inc. - The Life Sciences Report Interview with Ross Silver Moreá>

Expert Analysis

"RNN's story remains underexposed and the shares are undervalued." (6/22/15) Rexahn Pharmaceuticals Inc. - Yale Jen, Laidlaw & Company Moreá>

"STEM faces large opportunities in two markets." (6/22/15) StemCells Inc. - Caroline Corner, Cantor Fitzgerald Moreá>

"Signs point to fundamental strength for CTH." (6/22/15) Cynapsus Therapeutics Inc. - Jason Napodano, Zacks Small-Cap Research Moreá>

"We are initiating coverage on CPXX with a Buy rating." (6/19/15) Celator Pharmaceuticals Inc. - Ken Trbovich, MLV & Co Moreá>

"STEM has authorization to expand its Phase 2 SCI trial into Canada." (6/18/15) StemCells Inc. - Henry McCusker, Regenerative Medicine Investors Moreá>

"SNSS' current risk/reward is well-balanced." (6/17/15) Sunesis Pharmaceuticals Inc. - Hartaj Singh, BTIG Research Moreá>

"We are initiating coverage on HLTH with a Buy rating." (6/15/15) Nobilis Health Corp. - Charles Haff, Craig-Hallum Capital Moreá>

"CANF, an undervalued player, has upside for the long-term investor." (6/8/15) Can-Fite BioPharma Ltd. - Mark Breidenbach, H.C. Wainwright & Co. Moreá>